louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04608682: Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording
Official title: Effect of Intraoperative Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sugammadex
Motor Evoked Potentials
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2020-10-29
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transcranial motor evoked potential (TcMEP) monitoring is conventionally performed during surgery without or with minimal neuromuscular blockade (NMB) because of its potential interference with signal interpretation.The feasibility of TcMEP interpretation was assessed during partial NMB in adult neurosurgical patients. However, partial NMB may interfere record of TcMEP monitoring. Sugammadex is the first highly selective antagonist that can reverse NMB. This study aims to evaluate the success rate of intraoperative muscle relax reversal by sugammadex on intraoperative TceMEP recording.


Eligibility criteria: Inclusion Criteria:

* Age range from 18 to 65 years old
* American Society of Anesthesiologists (ASA) physical status I to II

Exclusion Criteria:

* BMI ≥35 kg/m-2
* History of epilepsy or use of antiepileptic drugs
* Personal history or family history of malignant hyperthermia
* Allergies to sugammadex; NMBs or other medication(s) used during general anesthesia
* Hemoglobin \<110 g/L
* TceMEP stimulation or recorded site infection
* Preoperative neurological dysfunction in both upper extremities
* Cardiac pacemaker
* Pregnancy and lactation

Primary outcomes:
measure: The success rate of TceMEPs
timeFrame: 5 minutes after first performing of TceMEPs
Secondary outcomes:
measure: Mean value of amplitudes of TceMEPs
timeFrame: 5, 10, 20, 30 and 60 minutes after first performing of TceMEPs
measure: Mean value of latencies of TceMEPs
timeFrame: 5, 10, 20, 30 and 60 minutes after first performing of TceMEPs.
measure: Thresholds of TceMEPs
timeFrame: 5 minutes after first performing of TceMEPs
measure: respiratory pressure
timeFrame: during the surgery
measure: Adverse effects of sugammadex
timeFrame: during the surgery
measure: Incidence of body movement
timeFrame: during the surgery
measure: Recurrence of neuromuscular blockade
timeFrame: time of extubation
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital, Capital Medical University
state: Beijing
Study officials:
References:
citation: Jian M, Ma B, Liu H, Wang C, Liang F, Zhou Y, Qiao H, Han R. Effect of intraoperative muscle relaxation reversal on the success rate of motor-evoked potential recording in patients undergoing spinal surgery: study protocol for a randomised controlled trial. BMJ Open. 2022 May 2;12(5):e056571. doi: 10.1136/bmjopen-2021-056571.
Clinical trial NCT06236282: ArtiSential® for Rectal Cancer Surgery
Official title: Safety and Efficacy of Flexible Articulated Instrument (ArtiSential®) in Laparoscopic Surgery for Rectal Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rectal Cancer
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2024-02-01
Enrollment: 93
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent laparoscopic resection for mid-to low rectal cancer located within 10 cm of the anal verge, performed by a single experienced surgeon between 2012 and 2022.

Brief summary: This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.


Eligibility criteria: Inclusion Criteria:

* mid-to-low rectal caner (witing 10cm of the anal verge)
* laparoscopic surgery

Exclusion Criteria:

* combined surgery
* recurrent rectal cancer surgery

Primary outcomes:
measure: Operation time
timeFrame: 0 week
Secondary outcomes:
measure: Long-term Survival
timeFrame: 2 year
measure: Anastomotic leakage (postop outcome)
timeFrame: 4 weeks
measure: TME quality (Operative outcome)
timeFrame: 0 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT00981682: Long Term Safety Assessment of SER120 in Patients With Nocturia
Official title: A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nocturia
Keywords: decrease in the number of nocturic episodes for patients with nocturia
Lead sponsor: Serenity Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2009-09-22
Enrollment: 376
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.


Eligibility criteria: Inclusion Criteria:

* Patients completed SPC-SER120-DB1-200901 and SPC-SER120-DB2-200902 studies
* Willing to provide consent for the study

Exclusion Criteria:

* Incontinence
* Diabetes Insipidus, Diabetes Mellitus
* CHF
* Renal Insufficiency
* Significant medical history which make participation unacceptable

Primary outcomes:
measure: Mean Serum Sodium
timeFrame: 40 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: Stephen M. Auerbach, MD
state: California
Study officials:
References:
Clinical trial NCT01432782: Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm
Official title: Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse Esophageal Spasm
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Esophageal Spasm, Diffuse
Keywords: Weight loss
Dysphagia
Esophageal hypermotility
Chest Pain
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2011-09-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study evaluates the effect of botulinum toxin 100 U or saline, injected endoscopically in the distal esophagus, on symptoms and manometry pattern in patients with diffuse esophageal spasm.

Detailed description: Patients are selected on the basis of a clinical diagnosis of diffuse esophageal spasm, based on endoscopy and manometry.

This is a sham-controlled cross-over study of injection of botulinum toxin or saline, in randomized order, in the distal esophagus.

All patients have undergone esophageal manometry which shows diffuse esophageal spasm, and a 24h pH monitoring/manometry to quantify acid reflux. All drugs prescribed to affect esophageal motility (nitrates, calcium antagonists) are stopped during the study. After randomisation, the patient will undergo standard esophageal manometry to assess baseline esophageal motility. On the same day the patient will be asked to fill out a set of symptom questionnaires including a dysphagia questionnaire. At endoscopy, the active treatment group receives 8 x 12.5 units, each in 0.5 ml, of botulinum toxin A which will be injected in the four quadrants of the esophagus at 2 and 5 cm above the lower esophageal sphincter. In the Sham group 8 \* 0.5 ml of physiologic serum will be injected. The randomisation will be performed at the endoscopy unit by a nurse otherwise not involved in the protocol.

After 1 month a stationary manometry and a new esophageal pH/manometry monitoring will be performed, followed by a second endoscopy with injection of saline or botulinum toxin in a cross-over mode. At the time of the second endoscopy each patient will fill out a dysphagia questionnaire. One month later, the dysphagia questionnaire is repeated.

Subsequently, follow-up will occur at the outpatient clinic after 6 and 12 months, with follow-up dysphagia questionnaires but no additional manometries or endoscopies, unless the clinical status deteriorates.

Eligibility criteria: Inclusion Criteria:

* Spastic motor disorder in the upper GI tract

Exclusion Criteria:

-

Primary outcomes:
measure: Dysphagia severity score
timeFrame: One month after treatment
Secondary outcomes:
measure: Manometry pattern
timeFrame: One month after treatment
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals Leuven
state: Vlaanderen
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Jan Tack, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06367920: Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain Development
Official title: Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pediatric ALL
Healthy
Lead sponsor: Bundang CHA Hospital
Sponsor class: OTHER
First posted: 2024-04-16
Enrollment: 2000
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects and patients 20 years old or younger who underwent imaging examinations performed at the Department of Rehabilitation Medicine at our hospital from January 2010 to December 2023 (patients who underwent brain MRI tests to determine the cause of developmental delay)

Brief summary: Retrospective study for development of imaging-genetics (brain imaging/genome big data) models and algorithms that are clinically explainable and have high predictive performance in brain research on pediatric developmental disorders

Detailed description: Retrospective study for development of imaging-genetics (brain imaging/genome big data) models and algorithms that are clinically explainable and have high predictive performance in brain research on pediatric developmental disorders

Eligibility criteria: Inclusion Criteria:

* Healthy subjects and patients 20 years old or younger who underwent imaging examinations performed at the Department of Rehabilitation Medicine at our hospital from January 2010 to December 2023 (patients who underwent brain MRI tests to determine the cause of developmental delay)

Exclusion Criteria:

* None

Primary outcomes:
measure: Brain magnetic resonance imaging
timeFrame: A time point at which imaging was performed between January 1, 2010 and December 31, 2024
Secondary outcomes:
measure: Medical records
timeFrame: A time point at which recording medical examinations was performed between January 1, 2010 and December 31, 2024
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: CHA Bundang Medical Center, CHA University
state: Gyeonggi-do
Study officials:
affiliation: Bundang CHA Hospital
name: Minyoung Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02700620: Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition
Official title: Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eating Disorders
Bulimia
Keywords: emotional eating
restrictive eating
body dissatisfaction
Lead sponsor: Linkoeping University
Sponsor class: OTHER_GOV
First posted: 2016-03-07
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Previous studies on Internet-based treatment with eating disorders have shown promising results.

Objective: The first aim of this study was to investigate the effects of a tailored therapist guided internet-based treatment for individuals with eating disorders. The second aim was to examine the role of knowledge acquisition.

Method: 138 participants were recruited. Screening consisted of online questionnaires followed by a telephone interview. A total of 92 participants were included after a semi-structured diagnostic interview and randomized to an 8 week treatment program (n=46) or to a control condition (n=46). Treatment consisted of individually prescribed cognitive behaviour therapy text modules in conjunction with online therapist guidance. The control group consisted of a waitlist who later received treatment.

Detailed description: As above

Eligibility criteria: Inclusion Criteria:

* Have reoccurring eating disorder uns or bulimia
* BMI above 17,5

Exclusion Criteria:

* Suicide prone
* Ongoing psychological treatment

Primary outcomes:
measure: Eating Disorders Examination Questionnaire
timeFrame: post (8 weeks)
Secondary outcomes:
measure: Quality of Life Inventory (QOLI)
timeFrame: Pre and post (8 weeks)
measure: Body Shape Questionnaire (BSQ)
timeFrame: post (8 weeks)
measure: Patient Health Questionnaire (PHQ-9)
timeFrame: post (8 weeks)
measure: Generalised Axiety Disorder Assessment (GAD-7)
timeFrame: post (8 weeks)
measure: Satisfaction With Life Scales (SWLS)
timeFrame: post (8 weeks)
measure: Expectancy/Credibility Questionnaire (CEQ)
timeFrame: post (8 weeks)
Other outcomes:
Locations:
Study officials:
References:
citation: Strandskov SW, Ghaderi A, Andersson H, Parmskog N, Hjort E, Warn AS, Jannert M, Andersson G. Effects of Tailored and ACT-Influenced Internet-Based CBT for Eating Disorders and the Relation Between Knowledge Acquisition and Outcome: A Randomized Controlled Trial. Behav Ther. 2017 Sep;48(5):624-637. doi: 10.1016/j.beth.2017.02.002. Epub 2017 Mar 2.
Clinical trial NCT01591720: Tailored Internet-delivered Cognitive Behaviour Therapy in Primary Care
Official title: Effectiveness Testing of a Tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Symptoms of Depression, Anxiety and Comorbid Problems
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Anxiety Disorders
Lead sponsor: Linkoeping University
Sponsor class: OTHER_GOV
First posted: 2012-05-04
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A tailored Internet-based cognitive-behavioural intervention is tested within a primary care clinic. Weekly measures of symptoms of depression and anxiety are obtained. Significant within-group effects are expected.

Detailed description: This Internet-based cognitive-behavioural therapy intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are "prescribed" following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.

The intervention is tested within a primary care clinic. Weekly measures of symptoms of depression and anxiety are obtained.

Eligibility criteria: Inclusion Criteria:

* Symptoms of depression and anxiety

Exclusion Criteria:

* Severe depression (based on interview)
* Severe psychiatric condition (e.g. psychosis or bipolar disorder)
* Suicidal (measured in diagnostic interview)

Primary outcomes:
measure: Patient Health Questionnaire 9 (PHQ-9)
timeFrame: 2 weeks before treatment starts
measure: Patient Health Questionnaire 9 (PHQ-9)
timeFrame: Weekly measures during treatment (for up to 16 weeks)
measure: Patient Health Questionnaire 9 (PHQ-9)
timeFrame: At treatment termination (after a maximum of 16 weeks)
measure: Generalised Anxiety Disorder Assessment 7 (GAD-7)
timeFrame: 2 weeks before treatment starts
measure: Generalised Anxiety Disorder Assessment 7 (GAD-7)
timeFrame: Weekly measures during treatment (for up to 16 weeks)
measure: Generalised Anxiety Disorder Assessment 7 (GAD-7)
timeFrame: At treatment termination (after a maximum of 16 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Linköping
country: Sweden
facility: Linköping University, Department of Behavioral Sciences and Learning
Study officials:
affiliation: Department of Behavioral Sciences and Learning, Linköping University
name: Gerhard Andersson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04198220: BIO|STREAM.ICM Obesity
Official title: BIO|STREAM.ICM Obesity, Submodule of the BIO|STREAM.ICM Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tachycardia Atrial
Atrial Fibrillation
Syncope
Bradycardia
Cryptogenic Stroke
Keywords: Obesity
BIOMONITOR
BIOMONITOR III
Syncope
Cryptogenic stroke
Atrial Fibrillation
Lead sponsor: Biotronik SE & Co. KG
Sponsor class: INDUSTRY
First posted: 2019-12-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patient population consists of obese patients (BMI \> 30 kg/m2) with an implantable cardiac monitor

Brief summary: The aim of the submodule study is to assess whether a high BMI may influence the sensing performance and the sECG quality of the BIOMONITOR.

Detailed description: This submodule of the BIO\|STREAM.ICM registry specifically investigates the performance of the BIOMONITOR in a subset of obese patients with a BMI \>30 kg/m2 in order to exclude any concerns regarding impaired ICM sensing performance. These concerns are founded in the increased distance between heart and device electrodes due to fat layers that may attenuate signal detection and therefore sensing performances of the ICM.

Eligibility criteria: Inclusion Criteria:

* Patient is already enrolled in the BIO\|STREAM.ICM registry
* Patient BMI \> 30

Exclusion Criteria:

* Patient clinically indicated for or already implanted with another cardiac active device

Primary outcomes:
measure: R-wave amplitude
timeFrame: 3 month
Secondary outcomes:
measure: Amount of 'noise burden'
timeFrame: 3 month
measure: P-wave visibility
timeFrame: 1 month and 3 month
Other outcomes:
measure: Incidence of arrhythmias
timeFrame: 3 month
Locations:
city: Castrovillari
country: Italy
facility: Ospedale Civile Ferrari
Study officials:
affiliation: Ospedale Civile Ferrari
name: Giovanni Bisignani, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02971020: Evaluating the Risk of Cognitive Impairment After Surgical and Transcatheter Aortic Valve Replacement
Official title: Proposal for Collection of Patient Data to Aid in Design of an Observational Study (i.e. Preparatory to Research) Evaluating Risk of Cognitive Impairment After Surgical and Transcatheter Valve Replacement.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Disease
Aortic Valve Stenosis
Cognitive Assessments
Valve Surgery
Transcatheter Valve Replacement
Surgical Valve Replacement
Lead sponsor: Center for Veterans Research and Education
Sponsor class: OTHER
Collaborators: name: Minneapolis Veterans Affairs Medical Center
First posted: 2016-11-22
Enrollment: 63
Sex: ALL
Maximum age (years): 104
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators are conducting a pilot study to compare cognitive outcomes among Veterans with severe aortic valve stenosis who are scheduled to undergo either aortic valve replacement.

Detailed description: The investigators are conducting a pilot study to compare cognitive outcomes in up to 60 Veterans with severe aortic valve stenosis who are scheduled to undergo either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) at the Minneapolis VA Health Care System. Participants will be administered a short battery of cognitive tests before and three months after TAVR or SAVR over/up to a two year study period.

Eligibility criteria: Inclusion Criteria:

* Severe aortic stenosis (AVA: 1 cm2 and/or mean gradient =or \> 40 mmHg and/or peak velocity \> 4 m/s)
* Scheduled to undergo either surgical or transcatheter aortic valve replacement at the Minneapolis VA Health Care System

Exclusion Criteria:

* Severe cognitive impairment at baseline (i.e. unable to understand or follow-up study procedures)
* Unable or unwilling to provide informed consent

Primary outcomes:
measure: Montreal Cognitive Assessment
timeFrame: Three Months
measure: Trail Making
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Minneapolis VA Health Care System
state: Minnesota
Study officials:
affiliation: Minneapolis Veterans Affairs Medical Center
name: Santiago Garcia, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Minneapolis Veterans Affairs Medical Center
name: Howard Fink, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00793520: Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Fibromyalgia
Keywords: fibromyalgia
milnacipran
Forest Laboratories
Lead sponsor: Forest Laboratories
Sponsor class: INDUSTRY
First posted: 2008-11-19
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of milnacipran on how the brain processes pain in patients with fibromyalgia and to assess the relationship between this effect and brain activation patterns during functional magnetic resonance imaging.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria
* Visual analog pain score between 40 and 90 mm
* Right-hand dominance

Exclusion Criteria:

* Suicidal risk
* Substance Abuse
* Pulmonary dysfunction
* Renal impairment
* Active cardiac disease
* Autoimmune disease
* Uncontrolled narrow-angle glaucoma
* Active liver disease
* Cancer
* Active peptic ulcer disease or a history of inflammatory bowel disease or celiac sprue
* Unstable endocrine disease
* Prostatic enlargement

Primary outcomes:
measure: Change in Medium Pressure Pain Threshold From Baseline to End of Treatment.
timeFrame: Week 0, 5, 7 and 12
Secondary outcomes:
measure: Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.
timeFrame: Weeks 0, 5, 7 and 12
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Forest Investigative Site
state: Michigan
Study officials:
affiliation: Forest Research Institute, a subsidiary of Forest Laboratories Inc
name: Allan Spera
role: STUDY_DIRECTOR
References: